Affluent Medical SA Achieves Major Milestones in H1 2024

Affluent Medical SA released its financial results for H1 2024, highlighting significant progress in its three key programs and several strategic agreements with Edwards Lifesciences. The financial runway has been extended until July 2025.

Notably, positive feedback from the FDA will expedite U.S. market access for the Kalios™ mitral ring device. Meanwhile, the Artus urinary sphincter pilot study has seen seven patient implants by mid-September. Developments also include advancements in patient assessments for the Epygon heart valve, with a fourfold increase in patient evaluations and new clinical centers activated.

The company secured an initial €15 million through agreements with Edwards Lifesciences, marking an important financial milestone. Despite a reported net loss of €9.4 million, the company's strategic moves and stakeholder support have fortified its operational stability.